Predicted mechanisms of resistance to mTOR inhibitors

R. T. Kurmasheva; S. Huang; P. J. Houghton

doi:10.1038/sj.bjc.6603353

Predicted mechanisms of resistance to mTOR inhibitors

R. T. Kurmasheva, S. Huang, P. J. Houghton

Research output: Contribution to journal › Short survey › peer-review

88 Scopus citations

Abstract

The serine/threonine kinase, mTOR (mammalian Target of Rapamycin) has become a focus for cancer drug development. Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell growth by retarding cells in G1 phase or potentially inducing apoptosis. Currently, both rapamycin and several analogues are being evaluated as anticancer agents in clinical trials. Results indicate that many human cancers have intrinsic resistance and tumours initially sensitive to rapamycins become refractory, demonstrating acquired resistance. Here, we consider mechanisms of resistance to inhibitors of mTOR.

Original language	English (US)
Pages (from-to)	955-960
Number of pages	6
Journal	British Journal of Cancer
Volume	95
Issue number	8
DOIs	https://doi.org/10.1038/sj.bjc.6603353
State	Published - Oct 23 2006
Externally published	Yes

Keywords

Cap-dependent translation
Clinical resistance
Kinase inhibitors
Mammalian target of rapamycin (mTOR)
Rapamycin
Resistance mechanisms

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/sj.bjc.6603353

Cite this

@article{ead74933bb7b401c93a3a5e18971ce21,

title = "Predicted mechanisms of resistance to mTOR inhibitors",

abstract = "The serine/threonine kinase, mTOR (mammalian Target of Rapamycin) has become a focus for cancer drug development. Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell growth by retarding cells in G1 phase or potentially inducing apoptosis. Currently, both rapamycin and several analogues are being evaluated as anticancer agents in clinical trials. Results indicate that many human cancers have intrinsic resistance and tumours initially sensitive to rapamycins become refractory, demonstrating acquired resistance. Here, we consider mechanisms of resistance to inhibitors of mTOR.",

keywords = "Cap-dependent translation, Clinical resistance, Kinase inhibitors, Mammalian target of rapamycin (mTOR), Rapamycin, Resistance mechanisms",

author = "Kurmasheva, {R. T.} and S. Huang and Houghton, {P. J.}",

note = "Funding Information: Original work cited from this laboratory was supported by USPHS grants CA77776, CA96696, CA23099, and CA21675 (Cancer Center Support Grant) from the National Cancer Institute, and by American, Lebanese, Syrian Associated Charities (ALSAC).",

year = "2006",

month = oct,

day = "23",

doi = "10.1038/sj.bjc.6603353",

language = "English (US)",

volume = "95",

pages = "955--960",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Predicted mechanisms of resistance to mTOR inhibitors

AU - Kurmasheva, R. T.

AU - Huang, S.

AU - Houghton, P. J.

N1 - Funding Information: Original work cited from this laboratory was supported by USPHS grants CA77776, CA96696, CA23099, and CA21675 (Cancer Center Support Grant) from the National Cancer Institute, and by American, Lebanese, Syrian Associated Charities (ALSAC).

PY - 2006/10/23

Y1 - 2006/10/23

N2 - The serine/threonine kinase, mTOR (mammalian Target of Rapamycin) has become a focus for cancer drug development. Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell growth by retarding cells in G1 phase or potentially inducing apoptosis. Currently, both rapamycin and several analogues are being evaluated as anticancer agents in clinical trials. Results indicate that many human cancers have intrinsic resistance and tumours initially sensitive to rapamycins become refractory, demonstrating acquired resistance. Here, we consider mechanisms of resistance to inhibitors of mTOR.

AB - The serine/threonine kinase, mTOR (mammalian Target of Rapamycin) has become a focus for cancer drug development. Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell growth by retarding cells in G1 phase or potentially inducing apoptosis. Currently, both rapamycin and several analogues are being evaluated as anticancer agents in clinical trials. Results indicate that many human cancers have intrinsic resistance and tumours initially sensitive to rapamycins become refractory, demonstrating acquired resistance. Here, we consider mechanisms of resistance to inhibitors of mTOR.

KW - Cap-dependent translation

KW - Clinical resistance

KW - Kinase inhibitors

KW - Mammalian target of rapamycin (mTOR)

KW - Rapamycin

KW - Resistance mechanisms

UR - http://www.scopus.com/inward/record.url?scp=33750211376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750211376&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6603353

DO - 10.1038/sj.bjc.6603353

M3 - Short survey

C2 - 16953237

AN - SCOPUS:33750211376

SN - 0007-0920

VL - 95

SP - 955

EP - 960

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 8

ER -

Predicted mechanisms of resistance to mTOR inhibitors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this